GlassScriptPhysician profile
Paul A Brittain
NPI 1184980989
$1,143.76
in general payments reported to CMS, 2019-2025
24 companies · $413 in 2025
The $413 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2020: $46.78 · 2021: $11.92 · 2023: $70.59 · 2024: $422 · 2025: $413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $863 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $863.09 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $159.15 | 2019-2025 | Opdualag, Opdivo, Krazati |
| Merck Sharp & Dohme LLC | $108.29 | 2019-2025 | Keytruda, Lynparza |
| Celgene Corporation | $83.21 | 2023-2025 | Reblozyl |
| Abbvie INC. | $82.09 | 2024-2025 | |
| Janssen Biotech, INC. | $80.09 | 2019-2025 | Erleada, Talvey |
| Astrazeneca Pharmaceuticals LP | $65.05 | 2024-2025 | Enhertu, Tagrisso |
| Genzyme Corporation | $60.08 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $49.51 | 2025 | |
| Kite Pharma, INC. | $49.11 | 2020-2024 | Yescarta |
| Gilead Sciences, INC. | $47.27 | 2021-2024 | |
| Sun Pharmaceutical Industries INC. | $41.77 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.35 | 2024-2025 | |
| Incyte Corporation | $29.46 | 2024 | Monjuvi |
| Springworks Therapeutics, INC. | $29.36 | 2024 | Ogsiveo |
| Tempus Ai, INC | $25.71 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $25.69 | 2019-2025 | |
| Agios Pharmaceuticals, INC. | $24.99 | 2024 | |
| Servier Pharmaceuticals LLC | $23.45 | 2025 | |
| Genentech USA, INC. | $22.54 | 2024 | Columvi, Lunsumio, Polivy |
| Puma Biotechnology, INC. | $21.00 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.40 | 2019 | |
| Astellas Pharma US INC | $18.95 | 2024 | Xtandi |
| Glaxosmithkline, LLC. | $18.47 | 2024 | Ojjaara |
| Jazz Pharmaceuticals INC. | $17.77 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Brittain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.